MiNK Therapeutics Announces Virtual Annual Shareholders Meeting
MiNK Therapeutics Announces Virtual Annual Shareholders Meeting
NEW YORK, June 05, 2024 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases, today announced that its Annual Shareholders Meeting will begin at 9:30 a.m. ET. on June 12, 2024, and will be conducted in a virtual format only. Registration for attendees will start at 9:15 a.m. ET.
2024年6月5日,美洲纳斯达克股票交易所(NASDAQ:INKT)临床阶段生物医药公司MiNK Therapeutics, Inc.宣布其年度股东大会将于2024年6月12日美国东部时间上午9:30开始,仅以虚拟形式进行。与会者的登记将于美国东部时间上午9:15开始。
To participate in the Annual Shareholders Meeting, shareholders should visit www.virtualshareholdermeeting.com/INKT2024 and enter the 16-digit control number found in their proxy materials. Guests may also access the meeting in listen-only mode. No control number is required for guests.
要参加股东大会,股东应前往www.virtualshareholdermeeting.com/INKT2024并输入在其代理材料中找到的16位控制号。访客也可以以仅听模式访问会议。对于访客,不需要控制号。
Webcast Information:
网络直播信息:
Date: Wednesday, June 12, 2024
日期:2024年6月12日星期三
Time: 9:30 a.m. ET
时间:美国东部时间上午9:30
A live webcast and replay will be accessible from the Company's website at https://investor.minktherapeutics.com/events-and-presentations and at www.virtualshareholdermeeting.com/INKT2024.
About MiNK Therapeutics
关于MiNK Therapeutics
MiNK Therapeutics is a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. MiNK is advancing a pipeline of both native and next generation engineered iNKT programs, with a platform designed to facilitate scalable and reproducible manufacturing for off-the-shelf delivery. The company is headquartered in New York, NY. For more information, visit https://minktherapeutics.com/ or @MiNK_iNKT. Information that may be important to investors will be routinely posted on our website and social media channels.
MiNK Therapeutics是一家临床阶段的生物制药公司,致力于开发并商业化变异自然杀伤T(iNKT)细胞疗法用于癌症和其他免疫介导性疾病的探索。MiNK正在推进一系列原生和下一代工程iNKT项目,该平台旨在促进可扩展和可重复制造的即插即用交付。公司总部位于纽约市。了解更多信息,请访问https://minktherapeutics.com/或@MiNK_iNKT。可能对投资者重要的信息将定期发布在我们的网站和社交媒体渠道上。
Investor Contact
投资者联系方式
917-362-1370
917-362-1370
Media Contact
媒体联系人
781-674-4428
781-674-4428
Source: MiNK Therapeutics
来源:MiNK治疗